ES
TEVA icon

Equitec Specialists’s Teva Pharmaceuticals TEVA Stock Holding History

Equitec Specialists’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-132,535
Closed -$2.04M – 111
2018
Q4 		$2.04M Buy
+132,535
New +$2.72M 0.57% 32

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Equitec Specialists's TEVA Position: Q1 2019 in Review

Equitec Specialists sold out of Teva Pharmaceuticals (TEVA) in Q1 2019, closing a stake of 132,535 shares — an estimated $2.04M sold.

Equitec Specialists first reported a position in TEVA in Q4 2018 and held it in 1 quarter. The position peaked at $2.04M in Q4 2018. 522 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

  • Equitec Specialists reported no remaining Teva Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Equitec Specialists sold 132,535 Teva Pharmaceuticals shares in Q1 2019, an estimated $2.04M.
  • Equitec Specialists first reported a position in Teva Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Equitec Specialists's Teva Pharmaceuticals position peaked at $2.04M in Q4 2018.
  • 522 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on Equitec Specialists's 13F filing for Q1 2019, filed 8 Apr 2019.